The efficiency of nanobubble therapy for oral mucositis during chemotherapy for the patients of advanced gastrointestinal cancer

The efficiency of nanobubble therapy for oral mucositis during chemotherapy for the patients of advanced gastrointestinal cancer - nanobubble therapy for oral mucositis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030385

Enrollment

Registered

2018-01-08

Start date

2018-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral mucositis during chemotherapy

Interventions

administration of nano-bubble water

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo anticancer drugs or radiotherapy for relapsed / advanced cancer

Exclusion criteria

Exclusion criteria: Patients who already have a oral mucositis at the beginning of the study, Patients with underlying diseases associated with oral mucositis such as collagen disease

Design outcomes

Primary

Measure	Time frame
Evaluation of oral mucositis with grade 2 or more according to CTCAEv 4.0 grade and patient questionnaire	—

Secondary

Measure	Time frame
Side effects, The most severe grade of oral mucositis, Period of disappearance of oral mucositis, Adverse events	—

Countries

Japan

Contacts

Public ContactTomoyuki Shibata

Fujita Health University Hospital Gastroenterology

shibat03@fujita-hu.ac.jp0562-93-9240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026